Guest guest Posted November 18, 2008 Report Share Posted November 18, 2008 BMS-214662, alone or in combination with IM or dasatinib, potently induced apoptosis of both proliferating and quiescent CML stem/progenitor cells with <1% recovery of Philadelphia positive LTC-IC. Normal stem/progenitor cells were relatively spared by BMS-214662, suggesting selectivity for leukemic stem/progenitor cells. The ability to induce selective apoptosis of leukemic stem/progenitor cells was unique to BMS-214662 and not seen with a structurally similar agent BMS-225975. BMS-214662 was cytotoxic against CML blast crisis stem/progenitor cells, particularly in combination with a TKI and equally effective in cell lines harbouring wild-type versus mutant BCR-ABL, including the T315I mutation. This is the first report of an agent with activity in resistant and blast crisis CML that selectively kills CML stem/progenitor cells through apoptosis and offers potential for eradication of chronic phase CML. http://cmlsource.ca/report_ash.php?lang=1http://bloodjournal.hematologylibrary.o\ rg/cgi/content/short/blood-2007-09-112573v1 Our friend from Canada, Skip is featured in Canada's CML Source. There are other interesting articles, also. http://cmlsource.ca/index.php?lang=1 If you want the low down on Zavie, well here is your opportunity. http://cmlsource.ca/zavie_miller.php?lang=1 Good reading, Lottie Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.